可测量残留病灶驱动的慢性淋巴细胞白血病一线治疗
该综述概述了慢性淋巴细胞白血病固定疗程治疗方案的进展,包括BCL2抑制剂联合抗CD20抗体或BTK抑制剂可实现深度缓解,并探讨了可测量残留病灶(MRD)在临床实践中的应用及未来前景。
要点
- 固定疗程治疗使用新型非化疗组合正在发展中。
- BCL2抑制剂联合抗CD20抗体或BTK抑制剂可实现深度缓解。
- 达到的MRD阴性水平已在多种情况下预测生存结局。
核心结论
- 固定疗程治疗策略和MRD检测在慢性淋巴细胞白血病中具有应用价值。
研究设计与样本
- 综述,未报告检索范围。
主要发现
- BCL2抑制剂联合抗CD20抗体或BTK抑制剂可实现深度缓解。
- MRD阴性水平已在免疫化疗和BCL2联合方案后等情况下预测生存结局。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The therapeutic paradigm for patients suffering from chronic lymphocytic leukaemia continues to rapidly evolve. Fixed duration therapies continue to develop using novel-novel non-chemotherapeutic combinations. B-cell lymphoma 2 (BCL2) inhibitors in combination with either anti-CD20 antibody or Bruton tyrosine kinase inhibitors are able to achieve deep responses. Levels of attained 'negative' measurable residual disease (MRD, also known as minimal residual disease) have been shown to predict survival outcomes in a number of settings, including following immunochemotherapy and BCL2-combinations. This review will outline the current data supporting fixed duration treatment approaches, the use of MRD in clinical practice, alongside the challenges and possibilities for MRD utility in the future.
引用
- Davids MS, Lin KH, Mohamed AI, et al. Measurable residual disease-driven treatment in first-line chronic lymphocytic leukaemia. Br J Haematol. 2024. PMID: 39538975. doi:10.1111/bjh.19902
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。